seed
Stage
1
Investors
About
Ephla Bio develops targeted B-cell therapeutics designed to address immune-related conditions using machine learning, offering clinician and researcher-led development for individuals with autoimmune disorders and blood cancers.
Explore Ephla Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.